Published in Gene Therapy Weekly, October 23rd, 2008
"To understand this process, we transfected Delta 264 CFTR plasmid cDNA into COS7 cells, and we noted that protein expression from the truncation mutant is barely detectable when compared with wild type or Delta F508 CFTR. Delta 264 CFTR protein expression increases dramatically when cells are treated with proteasome...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.